Oncolytic potential of the influenza virus in glioma therapy

Glioblastoma remains a tumor with one of the most unfavorable prognoses in clinical oncology. Given the insufficient effectiveness of standard treatment modalities, oncolytic virotherapy is being actively developed. However, the influenza virus has so far remained on the periphery of scientific attention. In this review, we outline the key characteristics and features of gliomas that determine their resistance to therapy; examine the immunosuppressive microenvironment and strategies for its modulation; summarize the status of clinical trials and preclinical development of viral agents for glioma therapy; and identify promising targets for combination approaches. Attention is paid to the potential of influenza-based vectors as oncolytic agents, with consideration of both the advantages and possible limitations of this platform.